RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
Paying $3.3bn
Executive Summary
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
You may also be interested in...
Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
Alnylam CEO Maraganore To Step Aside At End Of 2021
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
EU First To Approve Novartis’s Cholesterol Drug Leqvio
Novartis hopes its new RNAi-based therapy will be a blockbuster – but must eventually show it can cut heart attacks and cardiovascular deaths.